

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

| | |
|--|--|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| Karen L. MARFURT | 08/19/2004 |
| Mary Ellen WARCHAL-WINDHAM | 08/13/2004 |
| RECEIVING PARTY DATA | |
| Name: | Bayer HealthCare LLC |
| Street Address: | 555 White Plains Road |
| Internal Address: | 5th Floor |
| City: | Tarrytown |
| State/Country: | NEW YORK |
| Postal Code: | 10591 |
| PROPERTY NUMBERS Total: 1 | |
| Property Type | Number |
| Application Number: | 11660250 |
| CORRESPONDENCE DATA | |
| Fax Number: | (202)585-8080 |
| <i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i> | |
| Phone: | 202-585-8000 |
| Email: | dsias@nixonpeabody.com |
| Correspondent Name: | NIXON PEABODY LLP |
| Address Line 1: | 401 9th Street NW |
| Address Line 2: | Suite 900 |
| Address Line 4: | Washington DC, DISTRICT OF COLUMBIA 20004-2128 |
| ATTORNEY DOCKET NUMBER: | 247082-000111USPX |
| NAME OF SUBMITTER: | Jeffrey N. Townes |

CH \$40.00 11660250

Total Attachments: 2
 source=247082_111USPX_Assignment#page1.tif

501391116

**PATENT
 REEL: 025542 FRAME: 0336**

Application No. 11/660,250
Filing Date: June 14, 2007

ASSIGNMENT

For good and valuable consideration, and in accordance with my/our agreement(s) with Bayer Healthcare LLC, a corporation of the State of Delaware, USA, I/we, the undersigned, hereby sell, assign and transfer to Bayer Healthcare LLC, its successors and assigns ("Bayer"), my/our entire right, title and interest in and to any and all inventions described in the application for United States Letters Patent that is being executed by me/us herewith and entitled:

METHOD FOR DETERMINING THE CONCENTRATION OF
ANALYTES IN SAMPLES BY DIRECT MEDIATION OF ENZYMES

and my/our entire right, title and interest in and to said patent application; any and all applications for patents in foreign countries based on said application, including the right to file patent applications under the provisions of any convention or treaty, and specifically, without limitation, the International Convention and the European Patent Convention, claiming the priority of said application; any and all divisional, continuation, continuation-in-part, reissue, extension, substitute, or other application based on any of the aforesaid applications; and any and all patents, or reissues, additions or extensions thereof, issuing from any of the aforesaid applications and having effect in the United States or any other country; and I/we authorize and request the issuing authority to issue any and all of the aforesaid patents to Bayer, as the assignee of the entire right and interest therein.


I/We further covenant and agree that I/we am/are the sole/joint inventor(s) of the aforesaid invention(s); that I/we have the full right to convey the entire right in same to Bayer; that I/we have not executed and will not execute any instrument purporting to convey, mortgage, license, or otherwise transfer, in whole or in part, any interest in same to any party other than Bayer; that I/we, for myself/ourselves and for my/our heirs, executors and administrators, will, at the request of Bayer, assign, execute, and deliver, without further consideration, except for incurred expenses, any and all further patent applications, declarations, oaths, assignments, powers of attorney, and other documents, and will perform such other lawful acts, that may be deemed necessary by Bayer fully to secure its interest in the aforesaid and/or to obtain, maintain, and enforce the aforesaid patents; that I/we shall, at the request of Bayer, provide any and all documents, material, and information that may be deemed necessary by Bayer to obtain, maintain,

and enforce the aforesaid patents, including evidence for use in interference, opposition, reexamination, enforcement or validity litigation, or other legal proceedings in the United States or any other country or jurisdiction; and that I/we shall in general provide all information and do all things reasonable and necessary for securing to Bayer the full rights and benefits of its interest in the aforesaid inventions, application and patents.



Karen L. Marfurt

Date: 8-19-04



Mary Ellen Warchal-Windham

Date: Aug. 13, 2004

JR56004